Clinical and evidence-based considerations for choosing a pneumococcal conjugate vaccine in India: A narrative review
Immunization plays a crucial role in protecting children from life-threatening conditions such as pneumococcal disease. Pneumococcal disease can affect multiple organ systems and manifest as an invasive or noninvasive disease. Despite being preventable by vaccines, it remains a public health concern...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2025.2482285 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850273176882249728 |
|---|---|
| author | Vijay Yewale Pallab Chatterjee Sanjay M. Marathe Santosh Taur Sripriya Sathyanarayanan |
| author_facet | Vijay Yewale Pallab Chatterjee Sanjay M. Marathe Santosh Taur Sripriya Sathyanarayanan |
| author_sort | Vijay Yewale |
| collection | DOAJ |
| description | Immunization plays a crucial role in protecting children from life-threatening conditions such as pneumococcal disease. Pneumococcal disease can affect multiple organ systems and manifest as an invasive or noninvasive disease. Despite being preventable by vaccines, it remains a public health concern in India. The development of pneumococcal conjugate vaccines (PCVs) has helped reduce the burden of pneumococcal disease by overcoming the limitations of polysaccharide vaccines, especially in young children. Although immunogenicity is used as a proxy for the evaluation and approval of PCVs, results from immunogenicity studies have been bridged back to vaccine trial efficacy. Post-approval effectiveness and impact of new PCVs must be established. This review aims to consolidate evidence-based considerations that play a role in the evaluation of PCVs. Critical aspects related to the assessment of vaccines, their importance, and limitations in real-world contexts are discussed in this review. |
| format | Article |
| id | doaj-art-35d35bb14d9a489996e5e131cbcb1332 |
| institution | OA Journals |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-35d35bb14d9a489996e5e131cbcb13322025-08-20T01:51:35ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2025-12-0121110.1080/21645515.2025.2482285Clinical and evidence-based considerations for choosing a pneumococcal conjugate vaccine in India: A narrative reviewVijay Yewale0Pallab Chatterjee1Sanjay M. Marathe2Santosh Taur3Sripriya Sathyanarayanan4Department of Pediatrics, Apollo Children’s Hospital, Navi Mumbai, IndiaDepartment of Pediatrics, Apollo Multispeciality Hospital, Kolkata, IndiaDepartment of Pediatrics, Marathe Child Care Hospital, Mumbai, IndiaDepartment of Medical Affairs, Pfizer Ltd, Mumbai, IndiaDepartment of Medical Affairs, Pfizer Ltd, Mumbai, IndiaImmunization plays a crucial role in protecting children from life-threatening conditions such as pneumococcal disease. Pneumococcal disease can affect multiple organ systems and manifest as an invasive or noninvasive disease. Despite being preventable by vaccines, it remains a public health concern in India. The development of pneumococcal conjugate vaccines (PCVs) has helped reduce the burden of pneumococcal disease by overcoming the limitations of polysaccharide vaccines, especially in young children. Although immunogenicity is used as a proxy for the evaluation and approval of PCVs, results from immunogenicity studies have been bridged back to vaccine trial efficacy. Post-approval effectiveness and impact of new PCVs must be established. This review aims to consolidate evidence-based considerations that play a role in the evaluation of PCVs. Critical aspects related to the assessment of vaccines, their importance, and limitations in real-world contexts are discussed in this review.https://www.tandfonline.com/doi/10.1080/21645515.2025.2482285Immunitypneumococcal diseasevaccineefficacychild |
| spellingShingle | Vijay Yewale Pallab Chatterjee Sanjay M. Marathe Santosh Taur Sripriya Sathyanarayanan Clinical and evidence-based considerations for choosing a pneumococcal conjugate vaccine in India: A narrative review Human Vaccines & Immunotherapeutics Immunity pneumococcal disease vaccine efficacy child |
| title | Clinical and evidence-based considerations for choosing a pneumococcal conjugate vaccine in India: A narrative review |
| title_full | Clinical and evidence-based considerations for choosing a pneumococcal conjugate vaccine in India: A narrative review |
| title_fullStr | Clinical and evidence-based considerations for choosing a pneumococcal conjugate vaccine in India: A narrative review |
| title_full_unstemmed | Clinical and evidence-based considerations for choosing a pneumococcal conjugate vaccine in India: A narrative review |
| title_short | Clinical and evidence-based considerations for choosing a pneumococcal conjugate vaccine in India: A narrative review |
| title_sort | clinical and evidence based considerations for choosing a pneumococcal conjugate vaccine in india a narrative review |
| topic | Immunity pneumococcal disease vaccine efficacy child |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2025.2482285 |
| work_keys_str_mv | AT vijayyewale clinicalandevidencebasedconsiderationsforchoosingapneumococcalconjugatevaccineinindiaanarrativereview AT pallabchatterjee clinicalandevidencebasedconsiderationsforchoosingapneumococcalconjugatevaccineinindiaanarrativereview AT sanjaymmarathe clinicalandevidencebasedconsiderationsforchoosingapneumococcalconjugatevaccineinindiaanarrativereview AT santoshtaur clinicalandevidencebasedconsiderationsforchoosingapneumococcalconjugatevaccineinindiaanarrativereview AT sripriyasathyanarayanan clinicalandevidencebasedconsiderationsforchoosingapneumococcalconjugatevaccineinindiaanarrativereview |